Abstract
Summary
The North America sarcopenia treatment market is expected to reach USD 1,814,892.90 thousand by 2030 from USD 1,235,920.05 thousand in 2022, growing at a CAGR of 5.0% during the forecast period of 2023 to 2030.
Market Segmentation
North America Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route of Administration (Oral, Injectable, And Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) Country ( U.S., Canada, and Mexico) – Industry Trends and Forecast to 2030
Overview of North America Sarcopenia Treatment Market Dynamics
Drivers
• Rising prevalence of sarcopenia
• Growing awareness of sarcopenia and its detrimental effects on health
Restraint
• Lack of standardized diagnosis
Opportunity
• Strategic initiatives by market players
Market Players
Some of the major market players operating in the North America sarcopenia treatment market are:
• Abbott.
• Nestlé Health Science ( A subsidary of Nestlé S.A.)
• Novartis AG
• Sanofi
• Haleon Group of Companies.
• BASF SE
• Bio Thrive Sciences
• DSM
• Fermenta Biotech Limited
• AstaReal Co., Ltd.
• Metagenics
• Wellona Pharma
• The Vitamin Company India
• Healing Pharma India Pvt. Ltd.
• OPKO Health, Inc.
• MyMD Pharmaceuticals
• Regeneron Pharmaceuticals Inc.
• Biophytis
• ARMGO Pharma, Inc.
• Dystrogen Therapeutics Corp.
Table of Contents
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF THE NORTH AMERICA SARCOPENIA TREATMENT MARKET 14
1.4 CURRENCY AND PRICING 16
1.5 LIMITATIONS 16
1.6 MARKETS COVERED 16
2 MARKET SEGMENTATION 18
2.1 MARKETS COVERED 18
2.2 GEOGRAPHICAL SCOPE 19
2.3 YEARS CONSIDERED FOR THE STUDY 19
2.4 DBMR TRIPOD DATA VALIDATION MODEL 20
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 23
2.6 MULTIVARIATE MODELLING 24
2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 24
2.8 MARKET END USER COVERAGE GRID 25
2.9 DBMR MARKET POSITION GRID 26
2.10 SECONDARY SOURCES 28
2.11 ASSUMPTIONS 28
3 EXECUTIVE SUMMARY 29
4 PREMIUM INSIGHTS 32
4.1 PESTEL ANALYSIS 34
4.2 PORTER’S FIVE FORCES 35
5 NORTH AMERICA SARCOPENIA TREATMENT MARKET: REGULATIONS 36
5.1 REGULATIONS IN THE U.S 36
5.2 REGULATIONS IN CANADA 36
5.3 REGULATIONS IN MEXICO 37
6 MARKET OVERVIEW 38
6.1 DRIVERS 40
6.1.1 RISING PREVALENCE OF SARCOPENIA 40
6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 40
6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 41
6.2 RESTRAINTS 42
6.2.1 LACK OF STANDARDIZED DIAGNOSIS 42
6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 42
6.3 OPPORTUNITIES 43
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 43
6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 43
6.4 CHALLENGES 44
6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 44
6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 45
7 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 46
7.1 OVERVIEW 47
7.2 VITAMIN/DIETARY SUPPLEMENTS 50
7.2.1 VITAMIN SUPPLEMENTS 50
7.2.2 PROTEIN SUPPLEMENTS 50
7.2.3 FATTY ACID SUPPLEMENTS 51
7.2.4 CREATINE 51
7.2.5 WHEY PROTEINS 51
7.2.6 L-CARNITINE 51
7.2.7 SOY 51
7.2.8 BETA-ALANINE 51
7.2.9 OSTARINE 51
7.2.10 COLLAGEN PEPTIDES 51
7.2.11 LIGANDROL 51
7.2.12 BRANCH-CHAIN AMINO ACIDS 52
7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 52
7.2.14 MEDIUM CHAIN TRIGLYCERIDES 52
7.2.15 OTHERS 52
7.3 MEDICATIONS 52
7.3.1 OFF LABEL DRUGS 52
7.3.2 EMERGING DRUGS 53
- 7.3.2.1 ACE INHIBITORS 53
- 7.3.2.2 APPETITE STIMULANTS 53
- 7.3.2.3 ORAL ANTIDIABETIC DRUGS 53
- 7.3.2.4 OTHERS 53
7.4 OTHERS 53
8 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY TYPE 54
8.1 OVERVIEW 55
8.2 PRIMARY SARCOPENIA 58
8.2.1 VITAMIN/DIETARY SUPPLEMENTS 58
8.2.2 MEDICATIONS 58
8.2.3 OTHERS 58
8.3 SECONDARY SARCOPENIA 59
8.3.1 VITAMIN/DIETARY SUPPLEMENTS 59
8.3.2 MEDICATIONS 59
8.3.3 OTHERS 59
9 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY STAGES 60
9.1 OVERVIEW 61
9.2 PRE-SARCOPENIA 64
9.3 SARCOPENIA 64
9.4 SEVERE SARCOPENIA 64
10 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 65
10.1 OVERVIEW 66
10.2 ORAL 69
10.3 INJECTABLES 69
10.4 OTHERS 69
11 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY GENDER 70
11.1 OVERVIEW 71
11.2 MALE 74
11.3 FEMALE 74
12 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY END USER 75
12.1 OVERVIEW 76
12.2 HOSPITALS 79
12.2.1 PUBLIC 79
12.2.2 PRIVATE 79
12.3 SPECIALTY CLINICS 79
12.4 HOME HEALTHCARE 79
12.5 OTHERS 79
13 NORTH AMERICA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 80
13.1 OVERVIEW 81
13.2 DIRECT TENDER 84
13.3 RETAIL SALES 84
13.3.1 HOSPITAL PHARMACIES 84
13.3.2 ONLINE PHARMACIES 84
13.3.3 OTHERS 84
13.4 OTHERS 84
14 NORTH AMERICA SARCOPENIA TREATMENT MARKET BY COUNTRY 85
14.1 NORTH AMERICA 85
14.1.1 U.S 88
14.1.2 CANADA 93
14.1.3 MEXICO 98
15 NORTH AMERICA SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE 103
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 103
16 SWOT ANALYSIS 104
17 COMPANY PROFILE 105
17.1 ABBOTT 105
17.1.1 COMPANY SNAPSHOT 105
17.1.2 REVENUE ANALYSIS 105
17.1.3 PRODUCT PORTFOLIO 106
17.1.4 RECENT DEVELOPMENT 106
17.2 NESTLÉ HEALTH SCIENCE (A SUBSIDIARY OF NESTLÉ S.A.) 107
17.2.1 COMPANY SNAPSHOT 107
17.2.2 REVENUE ANALYSIS 107
17.2.3 PRODUCT PORTFOLIO 108
17.2.4 RECENT DEVELOPMENT 108
17.3 NOVARTIS AG 109
17.3.1 COMPANY SNAPSHOT 109
17.3.2 REVENUE ANALYSIS 109
17.3.3 PRODUCT PORTFOLIO 110
17.3.4 PIPELINE PORTFOLIO 110
17.3.5 RECENT DEVELOPMENT 110
17.4 SANOFI 111
17.4.1 COMPANY SNAPSHOT 111
17.4.2 REVENUE ANALYSIS 111
17.5 PRODUCT PORTFOLIO 112
17.5.1 RECENT DEVELOPMENT 112
17.6 HALEON GROUP OF COMPANIES 113
17.6.1 COMPANY SNAPSHOT 113
17.6.2 REVENUE ANALYSIS 113
17.6.3 PRODUCT PORTFOLIO 114
17.6.4 RECENT DEVELOPMENT 114
17.7 ASTAREAL CO., LTD 115
17.7.1 COMPANY SNAPSHOT 115
17.7.2 PRODUCT PORTFOLIO 115
17.7.3 RECENT DEVELOPMENT 115
17.8 BASF SE 116
17.8.1 COMPANY SNAPSHOT 116
17.8.2 REVENUE ANALYSIS 116
17.8.3 PRODUCT PORTFOLIO 117
17.8.4 RECENT DEVELOPMENT 117
17.9 BIOTHRIVE SCIENCES 118
17.9.1 COMPANY SNAPSHOT 118
17.9.2 PRODUCT PORTFOLIO 118
17.9.3 RECENT DEVELOPMENT 118
17.10 DSM 119
17.10.1 COMPANY SNAPSHOT 119
17.10.2 REVENUE ANALYSIS 119
17.10.3 PRODUCT PORTFOLIO 120
17.10.4 RECENT DEVELOPMENT 120
17.11 FERMENTA BIOTECH LIMITED 121
17.11.1 COMPANY SNAPSHOT 121
17.11.2 REVENUE ANALYSIS 121
17.11.3 PRODUCT PORTFOLIO 122
17.11.4 RECENT DEVELOPMENT 122
17.12 HEALING PHARMA INDIA PVT.IND 123
17.12.1 COMPANY SNAPSHOT 123
17.12.2 PRODUCT PORTFOLIO 123
17.12.3 RECENT DEVELOPMENT 123
17.13 METAGENICS 124
17.13.1 COMPANY SNAPSHOT 124
17.13.2 PRODUCT PORTFOLIO 124
17.13.3 RECENT DEVELOPMENT 124
17.14 THE VITAMIN COMPANY INDIA 125
17.14.1 COMPANY SNAPSHOT 125
17.14.2 PRODUCT PORTFOLIO 125
17.14.3 RECENT DEVELOPMENT 125
17.15 WELLONA PHARMA 126
17.15.1 COMPANY SNAPSHOT 126
17.15.2 PRODUCT PORTFOLIO 126
17.15.3 RECENT DEVELOPMENT 126
17.16 ARMGO PHARMA, INC 127
17.16.1 COMPANY SNAPSHOT 127
17.16.2 PIPELINE PORTFOLIO 127
17.16.3 RECENT DEVELOPMENT 127
17.17 BIOPHYTIS 128
17.17.1 COMPANY SNAPSHOT 128
17.17.2 PIPELINE PORTFOLIO 128
17.17.3 RECENT DEVELOPMENT 128
17.18 DYSTROGEN THERAPEUTICS CORP 129
17.18.1 COMPANY SNAPSHOT 129
17.18.2 PIPELINE PORTFOLIO 129
17.18.3 RECENT DEVELOPMENT 129
17.19 MYMD PHARMACEUTICALS 130
17.19.1 COMPANY SNAPSHOT 130
17.19.2 PIPELINE PORTFOLIO 130
17.19.3 RECENT DEVELOPMENT 130
17.20 OPKO HEALTH, INC 131
17.20.1 COMPANY SNAPSHOT 131
17.20.2 REVENUE ANALYSIS 131
17.20.3 PIPELINE PORTFOLIO 132
17.20.4 RECENT DEVELOPMENT 132
17.21 REGENERON PHARMACEUTICALS INC 133
17.21.1 COMPANY SNAPSHOT 133
17.21.2 REVENUE ANALYSIS 133
17.21.3 PIPELINE PORTFOLIO 134
17.21.4 RECENT DEVELOPMENT 134
18 QUESTIONNAIRE 135
19 RELATED REPORTS 138